Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Protocols for UTI Prevention Post-Botox
NCT03508921Phase 4Terminated
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jul 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trimethoprim + sulfamethoxazole in urinary tract infection (UTI) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Post Procedural- Urinary Tract Infection at 3 weeks. Started Jul 2018; status: terminated.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT03508921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508921.